New Immunomodulatory Therapeutic Vaccine that Targets Oligomeric Amyloid-β Could be Step Towards Halting Alzheimer’s Disease Progression
October 27, 2020 06:56 ET
|
Alzamend Neuro, Inc.
TAMPA, Fla., Oct. 27, 2020 (GLOBE NEWSWIRE) -- Alzheimer’s disease affects more than 5.8 million Americans at an estimated cost at over $305 billion in 2020 according to the Alzheimer's Association....
Alzamend Neuro™ Completes New Management Team for 2019
December 26, 2018 09:00 ET
|
Alzamend Neuro, Inc.
Tampa, Fla., Dec. 26, 2018 (GLOBE NEWSWIRE) -- Alzamend Neuro™, Inc. (Alzamend™ or the “Company”) announced today that it has appointed top-tier financial executive, Kenneth S. Cragun, CPA, as its...
Alzamend Neuro™ Appoints New CEO, Bio-Pharma Executive Stephan Jackman
November 20, 2018 09:00 ET
|
Alzamend Neuro, Inc.
Salt Lake City, Nov. 20, 2018 (GLOBE NEWSWIRE) -- Alzamend Neuro™, Inc. (Alzamend™ or the “Company”) announced today that it has appointed bio-pharma executive, Mr. Stephan Jackman, as its new Chief...